Rochester, Minn.-based Mayo Clinic and Deerfield, Ill.-based Baxter International, a global medical product company, have established a research and development collaboration aimed at advancing innovation across various therapeutic areas.
Under the arrangement, clinicians and researchers from both organizations will work together to advance new technologies and therapies to transform patient care. The collaboration will focus primarily on areas where breakthrough treatment options can be introduced and innovation can drive access to high-quality care. The first project will focus on kidney disease.
"We are excited about combining Mayo's clinical and research expertise with Baxter's ability to apply and scale innovation," said Gianrico Farrugia, MD, vice president of Mayo Clinic and CEO of Mayo Clinic in Jacksonville, Fla., where the collaboration will begin. "We are confident that this collaboration will help accelerate discoveries, development and application of life-changing therapies for patients."
The initial agreement is for five years, with a five-year renewal option. Additional details of the agreement were not disclosed.